8 results about "Timolol" patented technology

To provide a composition for lowering an eye pressure in a glaucoma patient.SOLUTION: In one aspect, the present disclosure provides a composition for lowering an eye pressure in a glaucoma patient, containing brimonidine or its pharmaceutically acceptable salt and timolol or its pharmaceutically acceptable salt. The composition of the present disclosure targets a patient of glaucoma. The composition of the present disclosure may be administered to a patient who has been treated with other glaucoma therapeutics but has not shown sufficient treatment effect.SELECTED DRAWING: None

The present invention relates to: a transparent composite eye drop containing carbonic anhydrase inhibitors, timolol or a pharmaceutically acceptable salt thereof, and cyclodextrin or a derivative thereof as an anti-recrystallization agent; and a preparation method therefor.

To provide formulation technology concerning an aqueous liquid preparation comprising brinzolamide and / or a salt thereof.SOLUTION: An aqueous liquid preparation containing brinzolamide and / or a salt thereof, 0.08-0.12 w / v% brimonidine tartrate, and timolol and / or a salt thereof.SELECTED DRAWING: None

The present invention relates to pharmaceutical composition comprising the beta 1 (β1)-receptor blocker timolol and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention may be useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and / or a symptom associated therewith.

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.

The present disclosure relates to colloidal drug aggregates (CDAs) that are further embedded in hydrogels for sustained local delivery. Preferred drugs include beta-blocker prodrugs and ROCK inhibitors for use in treating glaucoma. In particularly preferred embodiments, the CDAs comprise prodrugs of timolol or netarsudil in combination with phospholipid stabilizers. Preferred hydrogels include hyaluronan crosslinked using an oxime bond.

The present invention relates to a transparent composite eye drop containing a carbonic anhydrase inhibitor, timolol or a pharmaceutically acceptable salt thereof, and cyclodextrin or a derivative thereof as an anti-recrystallization agent, and to a method for preparing the same. The present invention relates to a transparent composite eye drop containing a carbonic anhydrase inhibitor, timolol or a pharmaceutically acceptable salt thereof, and cyclodextrin or a derivative thereof as an anti-recrystallization agent.

The invention discloses a topical pharmaceutical composition containing timolol and a preparation method thereof, and relates to the technical field of timolol topical composition;The raw material of the pharmaceutical composition is composed of timolol 0.1‑5wt%, white vaseline 19‑30wt%, liquid paraffin 46‑54wt%, and beeswax 17‑22wt%;The preparation method is to take liquid paraffin, beeswax, and white vaseline water bath heating and melting, stirring to obtain a mixture;Then add timolol under a specific constant temperature state, continue to stir;Finally, make after cooling to room temperature while stirring. The pharmaceutical composition provided by the invention can promote the active ingredient to penetrate the epidermis (stratum corneum) and dermis of the skin, to provide the active ingredient of a therapeutically effective amount;More importantly, the generation of impurities in the composition during storage is suppressed, and the time for the active ingredient to remain stable in the formula is significantly extended.